effects of adenovirus types 4 and 7 live, oral by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.alemtuzumabContraindicated (1)alemtuzumab, upadacitinib. Either increases effects of the other by immunosuppressive effects; risk of infection. Contraindicated.amobarbitalSerious - Use Alternative (1)amobarbital will decrease the level or effect of upadacitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid upadacitinib coadministration with strong CYP3A4 inducers.anakinraSerious - Use Alternative (1)anakinra, upadacitinib. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.anastrozoleMinor (1)anastrozole will increase the level or effect of upadacitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.antithymocyte globulin equineContraindicated (1)antithymocyte globulin equine, upadacitinib. Either increases effects of the other by immunosuppressive effects; risk of infection. Contraindicated.apalutamideSerious - Use Alternative (1)apalutamide will decrease the level or effect of upadacitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid upadacitinib coadministration with strong CYP3A4 inducers.atazanavirMonitor Closely (1)atazanavir will increase the level or effect of upadacitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Caution if upadacitinib is coadministered with strong CYP3A4 inhibitors.avacopanContraindicated (1)avacopan, upadacitinib. Either increases effects of the other by immunosuppressive effects; risk of infection. Contraindicated.axicabtagene ciloleucelSerious - Use Alternative (1)upadacitinib, axicabtagene ciloleucel. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.azathioprineContraindicated (1)azathioprine, upadacitinib. Either increases effects of the other by immunosuppressive effects; risk of infection. Contraindicated.baricitinibContraindicated (1)baricitinib, upadacitinib. Either increases effects of the other by immunosuppressive effects; risk of infection. Contraindicated.basiliximabContraindicated (1)basiliximab, upadacitinib. Either increases effects of the other by immunosuppressive effects; risk of infection. Contraindicated.BCG vaccine liveSerious - Use Alternative (1)upadacitinib decreases effects of BCG vaccine live by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.belataceptContraindicated (1)belatacept, upadacitinib. Either increases effects of the other by immunosuppressive effects; risk of infection. Contraindicated.belimumabContraindicated (1)belimumab, upadacitinib. Either increases effects of the other by immunosuppressive effects; risk of infection. Contraindicated.bosentanSerious - Use Alternative (1)bosentan will decrease the level or effect of upadacitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid upadacitinib coadministration with strong CYP3A4 inducers.brexucabtagene autoleucelSerious - Use Alternative (1)upadacitinib, brexucabtagene autoleucel. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.brodalumabContraindicated (1)brodalumab, upadacitinib. Either increases effects of the other by immunosuppressive effects; risk of infection. Contraindicated.butabarbitalSerious - Use Alternative (1)butabarbital will increase the level or effect of upadacitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid upadacitinib coadministration with strong CYP3A4 inducers.butalbitalSerious - Use Alternative (1)butalbital will decrease the level or effect of upadacitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid upadacitinib coadministration with strong CYP3A4 inducers.canakinumabContraindicated (1)canakinumab, upadacitinib. Either increases effects of the other by immunosuppressive effects; risk of infection. Contraindicated.carbamazepineSerious - Use Alternative (1)carbamazepine will decrease the level or effect of upadacitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid upadacitinib coadministration with strong CYP3A4 inducers.ceritinibSerious - Use Alternative (1)ceritinib will increase the level or effect of upadacitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.certolizumab pegolContraindicated (1)certolizumab pegol, upadacitinib. Either increases effects of the other by immunosuppressive effects; risk of infection. Contraindicated.chloramphenicolMonitor Closely (1)chloramphenicol will increase the level or effect of upadacitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Caution if upadacitinib is coadministered with strong CYP3A4 inhibitors.cholera vaccineSerious - Use Alternative (1)upadacitinib decreases effects of cholera vaccine by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.ciltacabtagene autoleucelSerious - Use Alternative (1)upadacitinib, ciltacabtagene autoleucel. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.clarithromycinMonitor Closely (1)clarithromycin will increase the level or effect of upadacitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Caution if upadacitinib is coadministered with strong CYP3A4 inhibitors.cobicistatMonitor Closely (1)cobicistat will increase the level or effect of upadacitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Caution if upadacitinib is coadministered with strong CYP3A4 inhibitors.conivaptanMonitor Closely (1)conivaptan will increase the level or effect of upadacitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Caution if upadacitinib is coadministered with strong CYP3A4 inhibitors.cyclophosphamideMinor (1)cyclophosphamide will increase the level or effect of upadacitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.cyclosporineContraindicated (1)cyclosporine, upadacitinib. Either increases effects of the other by immunosuppressive effects; risk of infection. Contraindicated.dabrafenibSerious - Use Alternative (1)dabrafenib will decrease the level or effect of upadacitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid upadacitinib coadministration with strong CYP3A4 inducers.darunavirMonitor Closely (1)darunavir will increase the level or effect of upadacitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Caution if upadacitinib is coadministered with strong CYP3A4 inhibitors.dengue vaccineSerious - Use Alternative (1)upadacitinib decreases effects of dengue vaccine by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.eculizumabContraindicated (1)eculizumab, upadacitinib. Either increases effects of the other by immunosuppressive effects; risk of infection. Contraindicated.efavirenzSerious - Use Alternative (1)efavirenz will decrease the level or effect of upadacitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid upadacitinib coadministration with strong CYP3A4 inducers.efgartigimod alfaContraindicated (1)efgartigimod alfa, upadacitinib. Either increases effects of the other by immunosuppressive effects; risk of infection. Contraindicated.efgartigimod/hyaluronidase SCContraindicated (1)efgartigimod/hyaluronidase SC, upadacitinib. Either increases effects of the other by immunosuppressive effects; risk of infection. Contraindicated.elagolixMonitor Closely (1)elagolix decreases levels of upadacitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Elagolix is a weak-to-moderate CYP3A4 inducer. Monitor CYP3A substrates if coadministered. Consider increasing CYP3A substrate dose if needed.emapalumabContraindicated (1)emapalumab, upadacitinib. Either increases effects of the other by immunosuppressive effects; risk of infection. Contraindicated.enzalutamideSerious - Use Alternative (1)enzalutamide will decrease the level or effect of upadacitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid upadacitinib coadministration with strong CYP3A4 inducers.etanerceptContraindicated (1)etanercept, upadacitinib. Either increases effects of the other by immunosuppressive effects; risk of infection. Contraindicated.etravirineSerious - Use Alternative (1)etravirine will decrease the level or effect of upadacitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid upadacitinib coadministration with strong CYP3A4 inducers.fexinidazoleSerious - Use Alternative (1)fexinidazole will increase the level or effect of upadacitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Fexinidazole inhibits CYP3A4. Coadministration may increase risk for adverse effects of CYP3A4 substrates.fingolimodContraindicated (1)fingolimod, upadacitinib. Either increases effects of the other by immunosuppressive effects; risk of infection. Contraindicated.fosphenytoinSerious - Use Alternative (1)fosphenytoin will decrease the level or effect of upadacitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid upadacitinib coadministration with strong CYP3A4 inducers.golimumabContraindicated (1)golimumab, upadacitinib. Either increases effects of the other by immunosuppressive effects; risk of infection. Contraindicated.guselkumabContraindicated (1)guselkumab, upadacitinib. Either increases effects of the other by immunosuppressive effects; risk of infection. Contraindicated.idecabtagene vicleucelSerious - Use Alternative (1)upadacitinib, idecabtagene vicleucel. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.idelalisibMonitor Closely (1)idelalisib will increase the level or effect of upadacitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Caution if upadacitinib is coadministered with strong CYP3A4 inhibitors.indinavirMonitor Closely (1)indinavir will increase the level or effect of upadacitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Caution if upadacitinib is coadministered with strong CYP3A4 inhibitors.inebilizumabSerious - Use Alternative (1)inebilizumab, upadacitinib. Either increases effects of the other by immunosuppressive effects; risk of infection. Contraindicated.infliximabContraindicated (1)infliximab, upadacitinib. Either increases effects of the other by immunosuppressive effects; risk of infection. Contraindicated.influenza virus vaccine quadrivalent, intranasalSerious - Use Alternative (1)upadacitinib decreases effects of influenza virus vaccine quadrivalent, intranasal by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.isoniazidMonitor Closely (1)isoniazid will increase the level or effect of upadacitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Caution if upadacitinib is coadministered with strong CYP3A4 inhibitors.istradefyllineMonitor Closely (1)istradefylline will increase the level or effect of upadacitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Istradefylline 40 mg/day increased peak levels and AUC of CYP3A4 substrates in clinical trials. This effect was not observed with istradefylline 20 mg/day. Consider dose reduction of sensitive CYP3A4 substrates.itraconazoleMonitor Closely (1)itraconazole will increase the level or effect of upadacitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Caution if upadacitinib is coadministered with strong CYP3A4 inhibitors.ivosidenibSerious - Use Alternative (1)ivosidenib will decrease the level or effect of upadacitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid upadacitinib coadministration with strong CYP3A4 inducers.ixekizumabSerious - Use Alternative (1)ixekizumab, upadacitinib. Either increases effects of the other by immunosuppressive effects; risk of infection. Contraindicated.ketoconazoleMonitor Closely (1)ketoconazole will increase the level or effect of upadacitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Caution if upadacitinib is coadministered with strong CYP3A4 inhibitors.larotrectinibMinor (1)larotrectinib will increase the level or effect of upadacitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.lenacapavirMonitor Closely (1)lenacapavir will increase the level or effect of upadacitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Lencapavir may increase CYP3A4 substrates initiated within 9 months after last SC dose of lenacapavir, which may increase potential risk of adverse reactions of CYP3A4 substrates.levoketoconazoleMonitor Closely (1)levoketoconazole will increase the level or effect of upadacitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Caution if upadacitinib is coadministered with strong CYP3A4 inhibitors.lisocabtagene maraleucelSerious - Use Alternative (1)upadacitinib, lisocabtagene maraleucel. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.lonafarnibSerious - Use Alternative (1)lonafarnib will increase the level or effect of upadacitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration with sensitive CYP3A substrates. If coadministration unavoidable, monitor for adverse reactions and reduce CYP3A substrate dose in accordance with product labeling.lopinavirMonitor Closely (1)lopinavir will increase the level or effect of upadacitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Caution if upadacitinib is coadministered with strong CYP3A4 inhibitors.lorlatinibSerious - Use Alternative (1)lorlatinib will decrease the level or effect of upadacitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid upadacitinib coadministration with strong CYP3A4 inducers.lumacaftor/ivacaftorSerious - Use Alternative (1)lumacaftor/ivacaftor will decrease the level or effect of upadacitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid upadacitinib coadministration with strong CYP3A4 inducers.measles (rubeola) vaccineSerious - Use Alternative (1)upadacitinib decreases effects of measles (rubeola) vaccine by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.measles mumps and rubella vaccine, liveSerious - Use Alternative (1)upadacitinib decreases effects of measles mumps and rubella vaccine, live by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.measles, mumps, rubella and varicella vaccine, liveSerious - Use Alternative (1)upadacitinib decreases effects of measles, mumps, rubella and varicella vaccine, live by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.mifepristoneMonitor Closely (1)mifepristone will increase the level or effect of upadacitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Caution if upadacitinib is coadministered with strong CYP3A4 inhibitors.mitotaneSerious - Use Alternative (1)mitotane will decrease the level or effect of upadacitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid upadacitinib coadministration with strong CYP3A4 inducers.mycophenolateSerious - Use Alternative (1)mycophenolate, upadacitinib. Either increases effects of the other by immunosuppressive effects; risk of infection. Contraindicated.nafcillinSerious - Use Alternative (1)nafcillin will decrease the level or effect of upadacitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid upadacitinib coadministration with strong CYP3A4 inducers.natalizumabSerious - Use Alternative (1)natalizumab, upadacitinib. Either increases effects of the other by immunosuppressive effects; risk of infection. Contraindicated.nefazodoneMonitor Closely (1)nefazodone will increase the level or effect of upadacitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Caution if upadacitinib is coadministered with strong CYP3A4 inhibitors.nelfinavirMonitor Closely (1)nelfinavir will increase the level or effect of upadacitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Caution if upadacitinib is coadministered with strong CYP3A4 inhibitors.ocrelizumabSerious - Use Alternative (1)ocrelizumab, upadacitinib. Either increases effects of the other by immunosuppressive effects; risk of infection. Contraindicated.ozanimodContraindicated (1)ozanimod, upadacitinib. Either increases effects of the other by immunosuppressive effects; risk of infection. Contraindicated.pacritinibSerious - Use Alternative (1)pacritinib, upadacitinib. Either increases effects of the other by immunosuppressive effects; risk of infection. Contraindicated.pegcetacoplanSerious - Use Alternative (1)pegcetacoplan, upadacitinib. Either increases effects of the other by immunosuppressive effects; risk of infection. Contraindicated.pentobarbitalSerious - Use Alternative (1)pentobarbital will decrease the level or effect of upadacitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid upadacitinib coadministration with strong CYP3A4 inducers.phenobarbitalSerious - Use Alternative (1)phenobarbital will decrease the level or effect of upadacitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate